These great stocks are great picks for investors as spring winds down.
Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market.
These highly advantaged businesses have what they need to keep raising their dividend payouts.
Income investors can buy in May and go away with these stocks.
The pharma-giant's shares could be poised for a trend reversal.
PFE earnings call for the period ending March 31, 2024.
A double beat on earnings, plus raised bottom-line guidance, made the company a hot item on Hump Day.
June S&P 500 E-Mini futures (ESM24) are down -0.42%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.73% this morning as mixed earnings and the prospect of higher-for-longer U.S. interest rates...
In late April, Pfizer (NYSE:PFE) and Genmab received approval from the United States Food and Drug Administration ...